NASDAQ:MLND
Delisted
Millendo Therapeutics Inc. Stock News
$3.26
+0 (+0%)
At Close: Aug 17, 2022
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
01:30pm, Monday, 10'th Feb 2020
Millendo Therapeutics appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer.
Baird likes drug wholesalers in premarket analyst action
12:58pm, Friday, 07'th Feb 2020
Arcturus Therapeutics (NASDAQ:ARCT) initiated with Buy rating and $19 (70% upside) price target at Guggenheim.BeyondSpring (NASDAQ:BYSI) initiated with Buy rating and $25 (45% upside) price target at
Will Millendo Continue to Surge Higher?
12:27pm, Wednesday, 15'th Jan 2020
As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.
Millendo Therapeutics Promotes Thomas Hoover to Chief Commercial Officer
01:30pm, Thursday, 09'th Jan 2020
Millendo Therapeutics announces the promotion of Thomas Hoover to the newly created position of Chief Commercial Officer
Millendo Therapeutics, Inc. (MLND): Hedge Funds In Wait-and-See Mode
03:40pm, Tuesday, 24'th Dec 2019
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Se
Geoff Nichol Appointed to Millendo Therapeutics Board of Directors
01:30pm, Thursday, 19'th Dec 2019
Geoff Nichol appointed to Millendo Therapeutics Board of Directors
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
12:14pm, Thursday, 05'th Dec 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration o
Millendo Therapeutics Announces Pricing of Public Offering of Common Stock
02:02am, Thursday, 05'th Dec 2019
Millendo Therapeutics Announces Pricing of Public Offering of Common Stock
Millendo Therapeutics Announces Proposed Public Offering of Common Stock
09:05pm, Wednesday, 04'th Dec 2019
Millendo Therapeutics Announces Proposed Public Offering of Common Stock
Millendo Therapeutics Reports Third Quarter 2019 Operating and Financial Results
01:30pm, Wednesday, 13'th Nov 2019
– Livoletide pivotal study in Prader-Willi syndrome completed recruitment for patients ages 8 to 65 and is on track to report topline results in 1H20 –
We Think Millendo Therapeutics (NASDAQ:MLND) Needs To Drive Business Growth Carefully
03:07pm, Friday, 01'st Nov 2019
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
11:34am, Thursday, 03'rd Oct 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 2) Dova Pharmaceuticals Inc (NASDAQ: DOVA ) Down In The
The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear
07:01pm, Sunday, 29'th Sep 2019
Biotech stocks came under selling pressure in the week ended Sept. 27 amid clinical data readouts and a handful of FDA decisions. AIM ImmunoTech Inc (NYSE: AIM ) was the worst decliner of the week, as
Millendo's Lead Asset Could Address Unmet PWS Need, Wedbush Says
07:53pm, Friday, 19'th Jul 2019
Although Millendo Therapeutics is a newer player in the biotech public market and the PWS market is small, it represents a so-far unmet need, Chico said in the note. About 10,000 patients suffer from
Hedge Funds Have Never Been This Bullish On Millendo Therapeutics, Inc. (MLND)
08:10pm, Thursday, 04'th Jul 2019
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter.
